Skip to content
buyWeak cluster of 2

Enrique Poradosu bought $9,980 of NVCT

Chief Science & Business Off at Nuvectis Pharma, Inc.. 2,000 shares at an average of $4.99, traded Nov 19, 2024, filed Nov 20, 2024.

Conviction score
18
Value
$9,980
2,000 shares
Holdings after
1,506,319
+0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $10k at market
    0
  • Relative to holdings
    Under 1% of holdings (0.1%)
    -5
  • Price context
    No price history yet
    0
  • Cluster
    2 insiders buying within 14 days
    +8
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -10.8%, 3m +54.8%, 6m +98.2%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

NVCTOct 9, 2026 · close 21.12
Since filing Nov 20, 2024: +316.6%SPY +34.8% · excess +281.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-24-120876, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 19, 2024POpen-market purchase
Common Stock
+2,000$4.99$9,9801,506,319Nov 20, 2024

Related signals

Other insiders at Nuvectis Pharma, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
59Moderate
NVCTbuy 2
Nuvectis Pharma, Inc.
Ron Bentsur
Chairman & CEO
$250k
12,500 shares
+0%
47Moderate
NVCTbuy 2
Nuvectis Pharma, Inc.
Marlio Charles Mosseri
owner
$916k
50,000 shares
+2%
48Moderate
NVCTbuy 4
Nuvectis Pharma, Inc.
Ron Bentsur
Chairman & CEO
$29k
5,000 shares
+0%
49Moderate
NVCTbuy 4
Nuvectis Pharma, Inc.
Matthew L. Kaplan
director
$64k
11,000 shares
+10%
49Moderate
NVCTbuy 4
Nuvectis Pharma, Inc.
Juan Sanchez
director
$75k
13,000 shares
+20%
57Moderate
NVCTbuy 4
Nuvectis Pharma, Inc.
Marlio Charles Mosseri
owner
$957k
154,770 shares
+5%
17Weak
NVCTbuy
Nuvectis Pharma, Inc.
Marlio Charles Mosseri
owner
$45k
5,603 shares
+0%
29Weak
NVCTbuy
Nuvectis Pharma, Inc.
Marlio Charles Mosseri
owner
$270k
33,442 shares
+1%
22Weak
NVCTbuy
Nuvectis Pharma, Inc.
Marlio Charles Mosseri
owner
$172k
21,167 shares
+1%
24Weak
NVCTbuy
Nuvectis Pharma, Inc.
Marlio Charles Mosseri
owner
$247k
27,662 shares
+1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Enrique Poradosu bought $9,980 of NVCT | InsiderTell